NCT01349452

Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Federal University of São Paulo · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Ganciclovir ophthalmic gel delivers multiple advantages in the treatment and prophylaxis of herpetic keratitis and shows potential for effectiveness against other viral ocular infections. The majority of adenoviral conjunctivitis will resolve without damaging vision, however, the investigators have no way to determine which cases will progress to ocular complications such as corneal infiltrates and pseudomembranes. Our purpose is to evaluate the efficacy of the Ganciclovir gel 0.15% in preventing ocular complications after adenoviral conjunctivitis.

Conditions

• Conjunctivitis, Viral
• Adenoviridae Infections

Interventions

Type	Name	Description
DRUG	Ganciclovir	Ganciclovir 0.15% Ophthalmic gel
DRUG	Artificial tear	Artificial tear 5 times per day

Timeline

• Start date: 2009-08-01
• Primary completion: 2009-12-01
• Completion: 2010-01-01
• First posted: 2011-05-06
• Last updated: 2011-05-06

Locations

1 site across 1 country: Brazil